PDCD1 and neoplasm: The presence of immune cell infiltrates, including tumor-infiltrating lymphocytes (TILs), in triple negative breast cancer (TNBC) with PD-1 or programmed death ligand-1 (PD-L1) expression suggest that ICIs could be effective in treating TNBC and enhancing anti-tumor immunity [10,11].